While all of these findings appear to support a potential increased risk of neurodegeneration with intravitreal anti-VEGF drug use, it is likely that this risk is relevant mostly to persons who have a high baseline risk of neurodegeneration (e.g., family history of Alzheimer’s disease, Parkinson’s disease, uncontrolled diabetes, etc.)and persons at risk of excessive VEGF inhibition with normal doses. Here, VEGFA is linked to diabetes mellitus.